The success of approved products for rare illnesses has opened the door for gene-based treatments of more prevalent diseases, finds Frost & Sullivan
MOUNTAIN VIEW, California, Dec. 17, 2015 /PRNewswire/ -- Currently, gene therapy is recovering across the biopharmaceutical industry as the quality and effectiveness of the technology shows gradual, but marked improvement. While safety concerns during the nascent phases affected technology adoption, novel delivery vector systems have facilitated the development of numerous safe therapeutic solutions and have given the technology a second wind.
Photo - http://photos.prnewswire.com/prnh/20151214/295683LOGO
Analysis from Frost & Sullivan, Advances in Gene Therapy (http://bit.ly/1TiVuGB), finds gene therapy can be effective for several emerging disease groups, including ocular diseases, diabetes, infectious illnesses and many of cancer types. Gene therapy for rare genetic diseases has been the most fruitful in terms of clinical trials. The success of these niche therapeutics has paved the way for similar applications for additional widespread diseases.
For complimentary access to more information on this research, please visit: http://bit.ly/1NlRhxq.
Until now, adverse side effects as well as high costs had made regulatory bodies and patients skeptical about gene therapy, while health insurance companies had been reluctant to provide reimbursements. However, an increasing number of collaborations among research and pharmaceutical companies to understand the potential applicability of gene therapy for prevalent diseases, such as cancer, will help develop novel and approved modes of treatment.
"With the rise in clinically proven remedies, it is likely insurance companies will begin to acknowledge the commercial advantage of gene therapy," said TechVision Senior Research Analyst Madhumitha Rangesa.
Improvements in vector technology and delivery systems will further enhance efficacy and clinical outcomes. Currently, the ocular diseases space is witnessing a rapid influx of companies equipped with the appropriate vector delivery systems capable of carrying small gene loads to specific target sites in the human body.
The use of combination therapies is another novel idea that will boost the therapeutic effects of gene technology. Competing industries, like cancer immunotherapy, are already shifting towards combination therapies within their own industry, with conventional or other burgeoning therapeutic fields.
Once the gene therapy industry bounces back with noteworthy products, governments around the world will step in to accelerate innovation. In the U.S., the growing emphasis on precision medicine capable of catering to a specific subset of people based closely on their genetic makeup is widening the scope for gene-based therapeutics.
"North America has the highest number of clinical trials in gene therapy largely due to the extensive focus on innovation and availability of funding," noted Rangesa. "In terms of market commercialization, Europe has overtaken North America with two products approved for commercialization within Europe and one approved for commercialization globally; however Asia is slowing catching up."
The global interest in the technology will attract investments and support the evolution of gene-based remedies from production and clinical trials to commercialization.
Advances in Gene Therapy, a part of the TechVision (http://ww2.frost.com/research/technology/health-wellness) subscription, offers an exhaustive analysis of the current trends in gene therapy, including technology challenges, market drivers and restraints in addition to the competitive landscape. It covers viral vector technologies, non-viral technologies as well as the diseases targeted. Furthermore, it lists the top companies working in the space with detailed information on their pipelines and recent activities.
Frost & Sullivan's global TechVision practice is focused on innovation, disruption and convergence and provides a variety of technology based alerts, newsletters and research services as well as growth consulting services. Its premier offering, the TechVision program, identifies and evaluates the most valuable emerging and disruptive technologies enabling products with near-term potential. A unique feature of the TechVision program is an annual selection of 50 technologies that can generate convergence scenarios, possibly disrupt the innovation landscape, and drive transformational growth. View a summary of our TechVision program by clicking on the following link: http://ifrost.frost.com/TechVision_Demo.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Advances in Gene Therapy
D6BA
Contact:
Kayla Belcher
Corporate Communications – North America
P: 210.247.2450
F: 210.348.1003
E: kayla.belcher@frost.com
http://www.frost.com
http://www.frost.com/techvision
Share this article